Cargando…

Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells

Triple negative breast cancer (TNBC) is a breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression. TNBC cells respond poorly to targeted chemotherapies currently in use and the mortality rate of TNBC remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Chimplee, Siriphorn, Roytrakul, Sittiruk, Sukrong, Suchada, Srisawat, Theera, Graidist, Potchanapond, Kanokwiroon, Kanyanatt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779136/
https://www.ncbi.nlm.nih.gov/pubmed/35056723
http://dx.doi.org/10.3390/molecules27020407
_version_ 1784637497400098816
author Chimplee, Siriphorn
Roytrakul, Sittiruk
Sukrong, Suchada
Srisawat, Theera
Graidist, Potchanapond
Kanokwiroon, Kanyanatt
author_facet Chimplee, Siriphorn
Roytrakul, Sittiruk
Sukrong, Suchada
Srisawat, Theera
Graidist, Potchanapond
Kanokwiroon, Kanyanatt
author_sort Chimplee, Siriphorn
collection PubMed
description Triple negative breast cancer (TNBC) is a breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression. TNBC cells respond poorly to targeted chemotherapies currently in use and the mortality rate of TNBC remains high. Therefore, it is necessary to identify new chemotherapeutic agents for TNBC. In this study, the anti-cancer effects of 7-α-hydroxyfrullanolide (7HF), derived from Grangea maderaspatana, on MCF-7, MDA-MB-231 and MDA-MB-468 breast cancer cells were assessed using MTT assay. The mode of action of 7HF in TNBC cells treated with 6, 12 and 24 µM of 7HF was determined by flow cytometry and propidium iodide (PI) staining for cell cycle analysis and annexin V/fluorescein isothiocyanate + PI staining for detecting apoptosis. The molecular mechanism of action of 7HF in TNBC cells was investigated by evaluating protein expression using proteomic techniques and western blotting. Subsequently, 7HF exhibited the strongest anti-TNBC activity toward MDA-MB-468 cells and a concomitantly weak toxicity toward normal breast cells. The molecular mechanism of action of low-dose 7HF in TNBC cells primarily involved G2/M-phase arrest through upregulation of the expression of Bub3, cyclin B1, phosphorylated Cdk1 (Tyr 15) and p53-independent p21. Contrastingly, the upregulation of PP2A-A subunit expression may have modulated the suppression of various cell survival proteins such as p-Akt (Ser 473), FoxO3a and β-catenin. The concurrent apoptotic effect of 7HF on the treated cells was mediated via both intrinsic and extrinsic modes through the upregulation of Bax and active cleaved caspase-7–9 expression and downregulation of Bcl-2 and full-length caspase-7–9 expression. Notably, the proteomic approach revealed the upregulation of the expression of pivotal protein clusters associated with G1/S-phase arrest, G2/M-phase transition and apoptosis. Thus, 7HF exhibits promising anti-TNBC activity and at a low dose, it modulates signal transduction associated with G2/M-phase arrest and apoptosis.
format Online
Article
Text
id pubmed-8779136
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87791362022-01-22 Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells Chimplee, Siriphorn Roytrakul, Sittiruk Sukrong, Suchada Srisawat, Theera Graidist, Potchanapond Kanokwiroon, Kanyanatt Molecules Article Triple negative breast cancer (TNBC) is a breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression. TNBC cells respond poorly to targeted chemotherapies currently in use and the mortality rate of TNBC remains high. Therefore, it is necessary to identify new chemotherapeutic agents for TNBC. In this study, the anti-cancer effects of 7-α-hydroxyfrullanolide (7HF), derived from Grangea maderaspatana, on MCF-7, MDA-MB-231 and MDA-MB-468 breast cancer cells were assessed using MTT assay. The mode of action of 7HF in TNBC cells treated with 6, 12 and 24 µM of 7HF was determined by flow cytometry and propidium iodide (PI) staining for cell cycle analysis and annexin V/fluorescein isothiocyanate + PI staining for detecting apoptosis. The molecular mechanism of action of 7HF in TNBC cells was investigated by evaluating protein expression using proteomic techniques and western blotting. Subsequently, 7HF exhibited the strongest anti-TNBC activity toward MDA-MB-468 cells and a concomitantly weak toxicity toward normal breast cells. The molecular mechanism of action of low-dose 7HF in TNBC cells primarily involved G2/M-phase arrest through upregulation of the expression of Bub3, cyclin B1, phosphorylated Cdk1 (Tyr 15) and p53-independent p21. Contrastingly, the upregulation of PP2A-A subunit expression may have modulated the suppression of various cell survival proteins such as p-Akt (Ser 473), FoxO3a and β-catenin. The concurrent apoptotic effect of 7HF on the treated cells was mediated via both intrinsic and extrinsic modes through the upregulation of Bax and active cleaved caspase-7–9 expression and downregulation of Bcl-2 and full-length caspase-7–9 expression. Notably, the proteomic approach revealed the upregulation of the expression of pivotal protein clusters associated with G1/S-phase arrest, G2/M-phase transition and apoptosis. Thus, 7HF exhibits promising anti-TNBC activity and at a low dose, it modulates signal transduction associated with G2/M-phase arrest and apoptosis. MDPI 2022-01-09 /pmc/articles/PMC8779136/ /pubmed/35056723 http://dx.doi.org/10.3390/molecules27020407 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chimplee, Siriphorn
Roytrakul, Sittiruk
Sukrong, Suchada
Srisawat, Theera
Graidist, Potchanapond
Kanokwiroon, Kanyanatt
Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells
title Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells
title_full Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells
title_fullStr Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells
title_full_unstemmed Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells
title_short Anticancer Effects and Molecular Action of 7-α-Hydroxyfrullanolide in G2/M-Phase Arrest and Apoptosis in Triple Negative Breast Cancer Cells
title_sort anticancer effects and molecular action of 7-α-hydroxyfrullanolide in g2/m-phase arrest and apoptosis in triple negative breast cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779136/
https://www.ncbi.nlm.nih.gov/pubmed/35056723
http://dx.doi.org/10.3390/molecules27020407
work_keys_str_mv AT chimpleesiriphorn anticancereffectsandmolecularactionof7ahydroxyfrullanolideing2mphasearrestandapoptosisintriplenegativebreastcancercells
AT roytrakulsittiruk anticancereffectsandmolecularactionof7ahydroxyfrullanolideing2mphasearrestandapoptosisintriplenegativebreastcancercells
AT sukrongsuchada anticancereffectsandmolecularactionof7ahydroxyfrullanolideing2mphasearrestandapoptosisintriplenegativebreastcancercells
AT srisawattheera anticancereffectsandmolecularactionof7ahydroxyfrullanolideing2mphasearrestandapoptosisintriplenegativebreastcancercells
AT graidistpotchanapond anticancereffectsandmolecularactionof7ahydroxyfrullanolideing2mphasearrestandapoptosisintriplenegativebreastcancercells
AT kanokwiroonkanyanatt anticancereffectsandmolecularactionof7ahydroxyfrullanolideing2mphasearrestandapoptosisintriplenegativebreastcancercells